Trial reportCirculation research2013
Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion.
Trial report in Circulation research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Prevalence of metabolic syndrome among people living with human immunodeficiency virus in sub-Saharan Africa: a systematic review and meta-analysis.Scientific reports · 2024Pooled it
- Efficacy and safety of obicetrapib in patients with dyslipidemia: An updated meta-analysis of randomized controlled trials.American journal of preventive cardiology · 2025Article
- Patterns of Lipid Abnormalities in Obesity: A Comparative Analysis in Normoglycemic and Prediabetic Obese Individuals.Journal of personalized medicine · 2024Article
- High-density lipoprotein in diabetes: Structural and functional relevance.Journal of diabetes investigation · 2024Review
- Obesity-associated metabolites in relation to type 2 diabetes risk: A prospective nested case-control study of the CARRS cohort.Diabetes, obesity & metabolism · 2022Article
- Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics.Signal transduction and targeted therapy · 2022Review
- High-density lipoprotein-cholesterol and incident type 2 diabetes mellitus among African Americans: The Jackson Heart Study.Diabetic medicine : a journal of the British Diabetic Association · 2022Article
- HDL as Bidirectional Lipid Vectors: Time for New Paradigms.Biomedicines · 2022Review
- Association of LDL:HDL ratio with prediabetes risk: a longitudinal observational study based on Chinese adults.Lipids in health and disease · 2022Observational
- HDL and Diabetes.Advances in experimental medicine and biology · 2022Article
- Interaction between CETP polymorphism and dietary insulin index and load in relation to cardiovascular risk factors in diabetic adults.Scientific reports · 2021Article
- HDL Cholesterol and Non-Cardiovascular Disease: A Narrative Review.International journal of molecular sciences · 2021Review
- The regulation of glucose and lipid homeostasis via PLTP as a mediator of BAT-liver communication.EMBO reports · 2020Article
- Role of High-Density Lipoproteins in Cholesterol Homeostasis and Glycemic Control.Journal of the American Heart Association · 2020Review
- Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.PloS one · 2020Article
- Genetic obesity increases pancreatic expression of mitochondrial proteins which regulate cholesterol efflux in BRIN-BD11 insulinoma cells.Bioscience reports · 2019Article
- Article
- The association between HDL particle concentration and incident metabolic syndrome in the multi-ethnic Dallas Heart Study.Diabetes & metabolic syndrome · 2017Article
- The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk.Lipids in health and disease · 2017Review
- HDL cholesterol: reappraisal of its clinical relevance.Clinical research in cardiology : official journal of the German Cardiac Society · 2017Review
Corrections and comments
- Commented on by
Authors and funding
11 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleHigh-density lipoprotein cholesterol elevation via cholesteryl ester transfer protein (CETP) inhibition represents a novel therapy for atherosclerosis, which also may have relevance for type 2 diabetes mellitus.
objectiveThe current study assessed the effects of a CETP inhibitor on postprandial insulin, ex vivo insulin secretion, and cholesterol efflux from pancreatic β-cells. METHODS AND
resultsHealthy participants received a daily dose of CETP inhibitor (n=10) or placebo (n=15) for 14 days in a randomized double-blind study. Insulin secretion and cholesterol efflux from MIN6N8 β-cells were determined after incubation with treated plasma. CETP inhibition increased plasma high-density lipoprotein cholesterol, apolipoprotein AI, and postprandial insulin. MIN6N8 β-cells incubated with plasma from CETP inhibitor-treated individuals (compared with placebo) exhibited an increase in both glucose-stimulated insulin secretion and cholesterol efflux over the 14-day treatment period.
conclusionsCETP inhibition increased postprandial insulin and promoted ex vivo β-cell glucose-stimulated insulin secretion, potentially via enhanced β-cell cholesterol efflux.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.